Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.

We aim to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Our pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.

Renovo signed an exclusive licensing agreement with Shire plc to develop and commercialise Juvista, its lead product for the reduction of scarring. Renovo retained all rights to Juvista in the European Union.

An HTML version of our latest Annual Report is at http://ar09.renovoreports.com

The Revise clinical trial of Juvista in scar revision surgery is currently ongoing in several European countries. For more information on participating centres in the UK, please contact the Renovo Clinical Trials Unit. For more information on participating centres in France, Italy, Spain and Denmark, please visit www.revisestudy.com.